Bryce Point Capital LLC Buys New Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Bryce Point Capital LLC purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 783 shares of the biopharmaceutical company’s stock, valued at approximately $558,000.

Other institutional investors have also recently made changes to their positions in the company. Rakuten Securities Inc. increased its stake in Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 15 shares during the last quarter. OFI Invest Asset Management purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $28,000. Avalon Trust Co bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $36,000. Crowley Wealth Management Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $36,000. Finally, Private Wealth Management Group LLC lifted its position in Regeneron Pharmaceuticals by 260.0% in the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 39 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of recent research reports. UBS Group cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the company from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Bernstein Bank decreased their target price on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Leerink Partners upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. Finally, Piper Sandler dropped their target price on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a report on Monday, January 27th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $966.88.

Regeneron Pharmaceuticals Stock Up 1.4 %

REGN stock opened at $625.60 on Thursday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $605.56 and a fifty-two week high of $1,211.20. The company has a market capitalization of $68.39 billion, a price-to-earnings ratio of 16.34, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The business’s 50 day moving average price is $680.43 and its two-hundred day moving average price is $786.93. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm earned $11.86 earnings per share. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.56%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.